BRAF and melanoma: Selective inhibitors of v-Raf murine sarcoma viral oncogene homolog B (BRAF), such as temozolomide and dacarbazine, and antibodies targeting T-lymphocyte-associated protein (CTLA4) have also been used in the modern melanoma therapies [20].